Pre-made Nivolumab benchmark antibody ( Whole mAb, anti-PDCD1/PD-1 therapeutic antibody, Anti-CD279/PD1/SLEB2/hSLE1 Antibody) for drug discovery and mechanism of action (MOA) research

Cat No.: GMP-Bios-ab-381

Pre-Made Nivolumab biosimilar, Whole mAb, Anti-PDCD1/PD-1 Antibody: Anti-CD279/PD1/SLEB2/hSLE1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Nivolumab, sold under the brand name Opdivo, is a medication used to treat a number of types of cancer. This includes melanoma, lung cancer, malignant pleural mesothelioma, renal cell carcinoma, Hodgkin lymphoma, head and neck cancer, urothelial carcinoma, colon cancer, esophageal squamous cell carcinoma, liver cancer, gastric cancer, and esophageal or gastroesophageal junction (GEJ) cancer. It is used by slow injection into a vein.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package List Price(In USD) Discount off Discount Price
GMP-Bios-ab-381-1mg 1mg 3090 Inquiry Inquiry

Size: 1mg | 10mg | 100mg


Products Name (INN Index) Pre-Made Nivolumab biosimilar, Whole mAb, Anti-PDCD1/PD-1 Antibody: Anti-CD279/PD1/SLEB2/hSLE1 therapeutic antibody
INN Name Nivolumab
FormatWhole mAb
Species ReactivityHuman
CH1 IsotypeIgG4
VD LCKappa
Highest_Clin_Trial (Jan '20)Approved
Est. StatusActive
100% SI Structure5ggq:HL/5wt9:HL/5ggr:HL:AB
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2012
Year Recommended2013
CompaniesAduro BioTech;AIO Studien gGmbH;Australian and New Zealand Urogenital and Prostate Cancer Group;Barbara Ann Karmanos Cancer Institute;Bavarian Nordic;Big Ten Cancer Research Consortium;Bristol-Myers Squibb;Canadian Cancer Trials Group;Celleron Therapeutics;Clatterbridge Cancer Centre NHS Foundation Trust;Clovis Oncology;Curie Institute;Daiichi Sankyo Company;Dana-Farber Cancer Institute;Duke University Medical Center;Eisai Inc;Eli Lilly;Emory University;European Thoracic Oncology Platform;Exelixis;Frontier Science foundation;Grupo Espanol Multidisciplinar de Melanoma;H. Lee Moffitt Cancer Center and Research Institute;Hellenic Genitourinary Cancer Group;Hoosier Cancer Research Network;HOVON Foundation;Incyte Corporation;Intergroupe Francophone de Cancerologie Thoracique;Janssen Biotech;Janssen Research & Development;Kansai Medical University;Kyoto Breast Cancer Research Network;M. D. Anderson Cancer Center;Massachusetts General Hospital;Medarex;Nantes University Hospital;National Cancer Center (Tokyo);National Cancer Centre (Singapore);National Cancer Institute (USA);Nektar Therapeutics;Neon Therapeutics;Netherlands Cancer Institute;Northwestern University;Ono Pharmaceutical;Pharmacyclics;PrECOG;Seattle Genetics;Sidney Kimmel Cancer Center;Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;Syneos Health;The University of Montreal Hospital Research Center;UNICANCER;University College London;University of Liverpool;University of Pittsburgh;University of Texas M. D. Anderson Cancer Center;Vanderbilt-Ingram Cancer Center;Zucero Therapeutics
Conditions ApprovedColorectal cancer;Gastric cancer;Head and neck cancer;Hodgkin's disease;Malignant melanoma;Non-small cell lung cancer;Renal cell carcinoma;Urogenital cancer;Liver cancer;Mesothelioma;Small cell lung cancer
Conditions ActiveBladder cancer;Fallopian tube cancer;Glioblastoma;Multiple myeloma;Oesophageal cancer;Ovarian cancer;Peritoneal cancer;Non-Hodgkin's lymphoma;Acute myeloid leukaemia;Adrenocortical carcinoma;Biliary cancer;Brain metastases;Breast cancer;Bronchopulmonary dysplasia;Cancer;Cervical cancer;Cholangiocarcinoma;Chronic lymphocytic leukaemia;CNS cancer;Diffuse large B cell lymphoma;Follicular lymphoma;Genitourinary disorders;Leucoplakia;Liver metastases;Meningeal carcinomatosis;Myelodysplastic syndromes;Nasopharyngeal cancer;Oropharyngeal cancer;Pancreatic cancer;Penile cancer;Prostate cancer;Soft tissue sarcoma;Solid tumours;Testicular cancer;Thyroid cancer;Uterine cancer;Uveal melanoma;Haematological malignancies;Lymphoma;Rectal cancer;Glioma
Conditions DiscontinuedChronic myeloid leukaemia;Hepatitis C;Sepsis
Development TechMedarex UltiMAb Mouse